CN1437947A - 氧氟沙星眼膏 - Google Patents

氧氟沙星眼膏 Download PDF

Info

Publication number
CN1437947A
CN1437947A CN 02153593 CN02153593A CN1437947A CN 1437947 A CN1437947 A CN 1437947A CN 02153593 CN02153593 CN 02153593 CN 02153593 A CN02153593 A CN 02153593A CN 1437947 A CN1437947 A CN 1437947A
Authority
CN
China
Prior art keywords
ofloxacin
gel
eye
eye ointment
ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 02153593
Other languages
English (en)
Other versions
CN1180776C (zh
Inventor
刘继东
高峨
马风明
姚东民
宋长海
刘立新
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenyang Xingqi Pharmaceutical Co Ltd
Original Assignee
刘继东
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 刘继东 filed Critical 刘继东
Priority to CNB021535930A priority Critical patent/CN1180776C/zh
Publication of CN1437947A publication Critical patent/CN1437947A/zh
Application granted granted Critical
Publication of CN1180776C publication Critical patent/CN1180776C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明涉及一种药物有效成分—氧氟沙星—首次制成凝胶型眼膏(迪可罗眼膏),应用于眼科细菌感染的治疗,旨在提高药物有效成分的生物利用度,增加疗效和用药安全性;本发明首次将氧氟沙星制成凝胶型眼膏,不仅解决了滴眼液易被泪液稀释、眼内停留时间短的问题;而且解决了全身给药治疗效果不理想的问题;主要技术内容是:氧氟沙星、卡泊姆、硼酸、氢化硬化蓖麻油、羟苯乙酯、丙二醇、透明质酸钠制成稳定的水溶性透明乳膏体,使用后在眼表形成一层透气的网状膜,作用持久,主要用于治疗由敏感菌引起的细菌性结膜炎,还可用于眼睑炎、麦粒肿、泪囊眼、睑板腺炎等眼科疾病。

Description

氧氟沙星眼膏
所属技术领域
本发明涉及一种药物有效成分——氧氟沙星——首次制成凝胶型眼膏,应用于眼科细菌感染的治疗,商品名为迪可罗眼膏。
背景技术
目前报导的在产的氧氟沙星眼科制剂有:0.3%氧氟沙星滴眼液、0.3%氧氟沙星眼膏,尚无氧氟沙星凝胶型眼膏的生产。
迪可罗是经批准的氧氟沙星眼膏的商品名。
发明内容
为了克服给药剂量大,口服药物难以通过血眼屏障的不足,发明一种眼用凝胶,眼科局部给药,不仅解决了滴眼液易被泪液稀释,眼内停留时间短的缺陷,且使用量少,提高药物有效成分的生物利用度,增加疗效和用药安全性。
本发明的技术方案是:氧氟沙星药物有效成分与卡泊姆凝胶基质和透明质酸钠溶液形成稳定的透明膏体,施用后在眼表形成一层透气的网状膜,作用持久。
氧氟沙星凝胶型眼膏是单方制剂,其化学名为:(±)-9-氟-2,3-二氢-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并[1,2,3-de]-[1,4]苯并噁嗪-6-羧酸眼用凝胶;通用名:氧氟沙星眼膏;商品名:迪可罗眼膏;英文名:LoxacinEye Gel;汉语拼音:Yangfushaxing Yangao;氧氟沙星药物成分与主要辅料成分及其按下列比例组成的应用于眼科疾患的制剂:其中含氧氟沙星为0.1-1.0%(w/w);含卡泊姆为0-3.0%(w/w);含氢化硬化蓖麻油为0-5.0%(w/w);含透明质酸钠为0-0.2%(w/w)。氧氟沙星药物有效成分,在酸性条件下与适量注射用水混合,研磨成极细粉末;分别与氯化钠、蓖麻油、羟苯乙酯、丙二醇、一起搅拌均匀,加水,加热使全部溶解。卡泊姆溶胀成水溶液,加适量硼酸制成透明乳膏,加入到上述冷却后的左旋氧氟沙星水溶液中,搅拌均匀,继续降温,加入透明质酸钠。搅拌至膏体透明,过滤,分装,包装(见附图)。另外,氧氟沙星药物有效成分与羟丙甲基纤维素系列、甲基纤维素系列、聚乙烯醇系列及聚乙烯吡咯烷酮等基质均可形成凝胶,卡泊姆系列基质效果最好。上述制备工艺中,其核心技术是:(1)氧氟沙星药物成分酸性条件下(pH=5.0-6.5)溶解,(2)与辅料成分混合加热溶解(温度范围60-80℃)是保证膏体透明的关键,(3)卡泊姆溶胀(浓度范围1.5-3.0%)制成透明乳膏,(4)透明质酸钠与膏体混合。
本发明的积极效果:氧氟沙星眼用凝胶的应用有以下优点:(1)、比口服给药成本低,口服每日给药量为300-600mg,而氧氟沙星凝胶型眼膏主药含量为0.3%,每日使用凝胶量约150-225mg,氧氟沙星每日使用量为0.75-1.25mg。(2)、氧氟沙星眼膏直接作用于患处,能充分有效地发挥作用,可避免口服药物治疗所带来的胃肠道刺激和其他副作用。(3)、相对于其它眼用制剂,凝胶剂具有无可比拟的优点,和滴眼液相比,氧氟沙星凝胶型眼膏不易被泪液稀释,在眼内停留时间长,有利于主药的充分吸收和利用;和凡士林基质的眼膏相比,氧氟沙星凝胶型眼膏水溶性好,易清洗,不污染衣物,使用方便。另一方面,氧氟沙星凝胶型眼膏不造成视野模糊,昼夜都可使用。
实施例处方1:
氧氟沙星……………0.3g      卡泊姆……………0.6g
氯化钠………………0.5g      硼酸………………1.0g
氢化硬化蓖麻油……1.0g      羟苯乙酯…………0.025g
丙二醇………………1.0g      透明质酸钠………0.05g
制成…………………………100.0g操作过程:
①.氧氟沙星研细,与氯化钠、蓖麻油、羟苯乙酯、丙二醇、一起搅拌均匀,加水,加热使全部溶解。
②.硼酸、卡泊姆、搅拌均匀,加入①中。
③.加热,搅拌均匀。
④.降温,40℃以下,加入透明质酸钠。
⑤.过滤,分装,包装,即得。处方2:
氧氟沙星………………0.1-1.0g    卡泊姆……………0.1-3.0g
氯化钠…………………0.1-1.0g    硼酸………………0.5-2.0g
氢化硬化蓖麻油………0.1-5.0g    羟苯乙酯…………0.025-0.1g
丙二醇…………………0.5-5.0g    透明质酸钠………0.01-0.1g
制成………………………100.0g操作过程:
①.氧氟沙星研细,与氯化钠、蓖麻油、羟苯乙酯、丙二醇、一起搅拌均匀,加水,加热使全部溶解。
②.硼酸、卡泊姆、搅拌均匀,加入①中。
③.加热,搅拌均匀。
④.降温,40℃以下,加入透明质酸钠。
⑤.过滤,分装,包装,即得。
图1为氧氟沙星眼膏制备工艺流程图。

Claims (2)

1.一种用于治疗细菌感染、应用于治疗眼科疾患的凝胶型氧氟沙星眼膏单方制剂,其化学名为:(±)-9-氟-2,3-二氢-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并[1,2,3-de]-[1,4]苯并噁嗪-6-羧酸眼膏;通用名:氧氟沙星眼膏;商品名:迪可罗眼膏;英文名:Levofloxacin Eye Gel;汉语拼音:Yangfushaxing Yangao;药物与主要辅料成分及其按下列比例组成的应用于眼科的制剂:其中含氧氟沙星为0.1-1.0%(w/w);含卡泊姆为0-3.0%(w/w);含蓖麻油为0-5.0%(w/w);含透明质酸钠为0-0.2%(w/w)。以及,与此含量比例相关的眼用制剂;将上述氧氟沙星药物有效成分,在酸性条件下与适量注射用水混合,研磨成极细粉末;分别与氯化钠、蓖麻油、羟苯乙酯、丙二醇、一起搅拌均匀,加水,加热使全部溶解。卡泊姆溶胀成水溶液,加适量硼酸制成透明乳膏,加入到上述冷却后的氧氟沙星水溶液中,搅拌均匀,继续降温,加入透明质酸钠。搅拌至膏体透明,过滤,分装,包装。另外,氧氟沙星药物有效成分与羟丙甲基纤维素系列、甲基纤维素系列、聚乙烯醇系列及聚乙烯吡咯烷酮等基质均可形成凝胶,卡泊姆系列基质效果最好。上述制备工艺中,其核心技术是:(1)氧氟沙星药物成分酸性条件下(pH=5.0-6.5)溶解,(2)与辅料成分混合加热溶解(温度范围60-80℃)是保证膏体透明的关键,(3)卡泊姆溶涨(浓度范围1.5-3.0%)制成透明乳膏,(4)透明质酸钠与膏体混合。
2.按照权利要求1所述的氧氟沙星眼用凝胶,其特征在于该药物有效成分氧氟沙星首次制成凝胶型眼膏,药物与主要辅料成分及其按下列比例组成的应用于眼科疾患治疗的制剂:其中氧氟沙星为其有效成分,浓度为0.1-1.0%(w/w);主要辅料含卡泊姆为0-3.0%(w/w);含氢化硬化蓖麻油为0-5.0%(w/w);含透明质酸钠为0-0.2%(w/w)。
CNB021535930A 2002-12-02 2002-12-02 凝胶型氧氟沙星眼膏 Expired - Lifetime CN1180776C (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB021535930A CN1180776C (zh) 2002-12-02 2002-12-02 凝胶型氧氟沙星眼膏

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB021535930A CN1180776C (zh) 2002-12-02 2002-12-02 凝胶型氧氟沙星眼膏

Publications (2)

Publication Number Publication Date
CN1437947A true CN1437947A (zh) 2003-08-27
CN1180776C CN1180776C (zh) 2004-12-22

Family

ID=27672199

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB021535930A Expired - Lifetime CN1180776C (zh) 2002-12-02 2002-12-02 凝胶型氧氟沙星眼膏

Country Status (1)

Country Link
CN (1) CN1180776C (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006130A3 (en) * 2007-06-28 2009-09-17 Bausch & Lomb Incorporated Salt free hyaluronate ophthalmic solution
CN101618018B (zh) * 2008-07-01 2011-11-09 上海通用药业股份有限公司 一种硝酸咪康唑微粒及其制备方法和药物组合物
WO2013122801A1 (en) * 2012-02-13 2013-08-22 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
CN104523575A (zh) * 2014-12-24 2015-04-22 昆明振华制药厂有限公司 一种盐酸羟苄唑眼用凝胶剂及其制备方法

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006130A3 (en) * 2007-06-28 2009-09-17 Bausch & Lomb Incorporated Salt free hyaluronate ophthalmic solution
CN101618018B (zh) * 2008-07-01 2011-11-09 上海通用药业股份有限公司 一种硝酸咪康唑微粒及其制备方法和药物组合物
WO2013122801A1 (en) * 2012-02-13 2013-08-22 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
US9278132B2 (en) 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
CN104523575A (zh) * 2014-12-24 2015-04-22 昆明振华制药厂有限公司 一种盐酸羟苄唑眼用凝胶剂及其制备方法
CN104523575B (zh) * 2014-12-24 2017-09-26 昆明振华制药厂有限公司 一种盐酸羟苄唑眼用凝胶剂及其制备方法

Also Published As

Publication number Publication date
CN1180776C (zh) 2004-12-22

Similar Documents

Publication Publication Date Title
CN102078284B (zh) 一种含加替沙星的眼用凝胶剂及其制备方法
CN100430069C (zh) 一种中药及其复方的可逆性热凝胶化水性药物组合物
CN101564375A (zh) 一种中药眼用即型凝胶
EP2922528B1 (en) Topical dapsone and dapsone/adapalene compositions and methods for use thereof
KR20020021320A (ko) 안과용 의약 조성물
CN101716214A (zh) 含有蒲公英提取物的药物组合物及其新用途和制备方法
JP2024016022A (ja) 皮膚炎および炎症性皮膚状態のためのカンナビノイド投薬レジメン
CN1456350A (zh) 环孢素眼用凝胶
CN101342174B (zh) 一种酞丁安/达克罗宁的复方局部用制剂
CN101926762B (zh) 富马酸卢帕他定滴眼液及其制备方法
CN1180776C (zh) 凝胶型氧氟沙星眼膏
CN100388923C (zh) 一种治疗急性角膜炎、缓解视疲劳的中药制剂及其制备工艺
CN1456157A (zh) 左旋氧氟沙星眼用凝胶
CN112546083A (zh) 一种含有七叶皂苷钠的消肿镇痛复方制剂及其制备方法
CN1206988C (zh) 硫酸阿托品眼用凝胶
JP4904687B2 (ja) 眼科用組成物
WO2024041083A1 (zh) 一种抗真菌溶液及其制备方法和应用
CN1562030A (zh) 以hpmc为基质的加替沙星眼用凝胶剂及其制备方法
CN115337258A (zh) 一种盐酸地尔硫卓的药物组合物、制备方法及其应用
CN1194685C (zh) 硝酸毛果芸香碱眼用凝胶
CN1194686C (zh) 氟康唑滴眼液
CN113713000B (zh) 用于治疗疮痈、烧烫伤和痤疮的主药成分组合物、缓控释药物制剂及其制备方法和应用
JPS63174935A (ja) リゾチーム含有化粧品組成物
CN1931349A (zh) 一种含有莪术油的抗病毒滴眼液
CN113413331B (zh) 祛痘组合物及其制剂和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Assignee: SHENYANG SINQI PHARMACEUTICAL Co.,Ltd.

Assignor: Liu Jidong

Contract fulfillment period: 2008.9.29 to 2013.9.29

Contract record no.: 2008210000056

Denomination of invention: Ofloxacin eye ointment

Granted publication date: 20041222

License type: Exclusive license

Record date: 20081105

LIC Patent licence contract for exploitation submitted for record

Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.9.29 TO 2013.9.29; CHANGE OF CONTRACT

Name of requester: SHENYANG XING QI PHARMACEUTICAL CO., LTD.

Effective date: 20081105

EE01 Entry into force of recordation of patent licensing contract

Assignee: SHENYANG SINQI PHARMACEUTICAL Co.,Ltd.

Assignor: Liu Jidong

Contract fulfillment period: 2008.9.29 to 2013.9.29

Contract record no.: 2008210000056

Denomination of invention: Ofloxacin eye ointment

Granted publication date: 20041222

License type: Exclusive license

Record date: 20081105

LIC Patent licence contract for exploitation submitted for record

Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.9.29 TO 2013.9.29; CHANGE OF CONTRACT

Name of requester: SHENYANG XING QI PHARMACEUTICAL CO., LTD.

Effective date: 20081105

ASS Succession or assignment of patent right

Owner name: SHENYANG XINGQI MEDICINE CO., LTD.

Free format text: FORMER OWNER: LIU JIDONG

Effective date: 20111013

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20111013

Address after: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China

Patentee after: SHENYANG SINQI PHARMACEUTICAL Co.,Ltd.

Address before: 110027 -4, No. 12, 3 Street, Shenyang economic and Technological Development Zone, Liaoning, Shenyang

Patentee before: Liu Jidong

C56 Change in the name or address of the patentee

Owner name: SHENYANG SINQI EYE PHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME: SHENYANG XINGQI MEDICINE CO., LTD.

CP03 Change of name, title or address

Address after: 110024, 4, 12, three street, Shenyang economic and Technological Development Zone

Patentee after: SHENYANG XINGQI PHARMACEUTICAL Co.,Ltd.

Address before: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China

Patentee before: SHENYANG SINQI PHARMACEUTICAL Co.,Ltd.

CX01 Expiry of patent term

Granted publication date: 20041222

CX01 Expiry of patent term